» Articles » PMID: 28212790

The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease

Overview
Journal Adv Parasitol
Specialty Parasitology
Date 2017 Feb 19
PMID 28212790
Citations 206
Authors
Affiliations
Soon will be listed here.
Abstract

The echinococcoses are chronic, parasitic diseases that are acquired after ingestion of infective taeniid tapeworm eggs from certain species of the genus Echinococcus. Cystic echinococcosis (CE) occurs worldwide, whereas, alveolar echinococcosis (AE) is restricted to the northern hemisphere, and neotropical echinococcosis (NE) has only been identified in Central and South America. Clinical manifestations and disease courses vary profoundly for the different species of Echinococcus. CE presents as small to large cysts, and has commonly been referred to as 'hydatid disease', or 'hydatidosis'. A structured stage-specific approach to CE management, based on the World Health Organization (WHO) ultrasound classification of liver cysts, is now recommended. Management options include percutaneous sterilization techniques, surgery, drug treatment, a 'watch-and-wait' approach or combinations thereof. In contrast, clinical manifestations associated with AE resemble those of a 'malignant', silently-progressing liver disease, with local tissue infiltration and metastases. Structured care is important for AE management and includes WHO staging, drug therapy and long-term follow-up for at least a decade. NE presents as polycystic or unicystic disease. Clinical characteristics resemble those of AE, and management needs to be structured accordingly. However, to date, only a few hundreds of cases have been reported in the literature. The echinococcoses are often expensive and complicated to treat, and prospective clinical studies are needed to better inform case management decisions.

Citing Articles

A ten-year evaluation of central nervous system cystic echinococcosis in a highly endemic area of Iran: Molecular epidemiology and clinicopathological characteristics.

Najjari M, Manesh A, Rezaeian S, Farrash B, Mohammadi M, Ebrahimipour M Parasite Epidemiol Control. 2025; 28:e00414.

PMID: 39968324 PMC: 11833634. DOI: 10.1016/j.parepi.2025.e00414.


Efficacy and safety of pseudolaric acid B against and in a murine infection model.

Dawa Z, Zhai T, Liu C, Fan H Front Med (Lausanne). 2025; 12:1503472.

PMID: 39944494 PMC: 11813755. DOI: 10.3389/fmed.2025.1503472.


A Comprehensive Analysis of Infections in Children and Adolescents: Results of a 7-Year Retrospective Study and Literature Review.

Mihai C, Lupu A, Chisnoiu T, Balasa A, Baciu G, Lupu V Pathogens. 2025; 14(1).

PMID: 39861014 PMC: 11768134. DOI: 10.3390/pathogens14010053.


Expression of TNF-α, VEGF-A and Microvessel Density in Cerebral Alveolar Echinococcosis and Their Correlation with Perilesional Brain Edema.

Wumier W, Abulizi A, Wu P, Jinsihan N, Wang Y, Duysenbi S Acta Parasitol. 2025; 70(1):33.

PMID: 39853563 DOI: 10.1007/s11686-024-00943-7.


Investigation of the threonine metabolism of Echinococcus multilocularis: The threonine dehydrogenase as a potential drug target in alveolar echinococcosis.

Kaethner M, Zumstein P, Muller J, Preza M, Grossenbacher P, Bartetzko A Int J Parasitol Drugs Drug Resist. 2025; 27:100581.

PMID: 39847910 PMC: 11795093. DOI: 10.1016/j.ijpddr.2025.100581.